Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.

Aggiungi a watchlist

37,62

-1,59

(-4,06%)

Alla chiusura: 04:00PM EDT

37,62

0,00

(0,00%)

Dopo ore:

04:20PM EDT

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	5,491B
Beta (5 anni mensile)	0,41
Rapporto PE (ttm)	N/D
EPS (ttm)	-2,67
Prossima data utili	07 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	56,19

Tutte

GlobeNewswire
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patients have already expressed interest in participating BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insigh
GlobeNewswire
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community.